Zura Bio Limited/$ZURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Ticker
$ZURA
Sector
Primary listing
Employees
40
Headquarters
Website
Zura Bio Limited Metrics
BasicAdvanced
$334m
-
-$1.07
0.03
-
Price and volume
Market cap
$334m
Beta
0.03
52-week high
$7.44
52-week low
$1.00
Average daily volume
854k
Financial strength
Current ratio
19.328
Quick ratio
19.208
Profitability
EBITDA (TTM)
-81.435
Management effectiveness
Return on assets (TTM)
-25.39%
Return on equity (TTM)
-40.96%
Valuation
Price to book
1.54
Price to tangible book (TTM)
1.54
Price to free cash flow (TTM)
-4.782
Free cash flow yield (TTM)
-20.91%
Free cash flow per share (TTM)
-0.735
Growth
Earnings per share change (TTM)
49.52%
3-year earnings per share growth (CAGR)
-69.27%
Zura Bio Limited News
AllArticlesVideos
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
Business Wire·1 month ago
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Business Wire·1 month ago
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs